Allergy Therapeutics has announced publication of 1-year follow up results of its mite allergoid immunotherapy Acarovac Plus™, in the peer-reviewed journal Immunotherapy. The results, in our view, are compelling. The company reports a statistically significant reduction in symptom scores observed at both followup visits (4 weeks and 1 year), with >50% reduction in symptom scores recorded after 1 year. We consider this plays well to the key points of Allergy’s platform which we
